Table 10.
Dry powder coated lactose incorporated DPI formulations.
| Drug | Coating mechanism and coating time (min) | Key ingredients | PSD (μm) | Device and flow rate (l/min) | % FPF | References |
|---|---|---|---|---|---|---|
| SS | Wurster Fluidized Bed and 180 | Pharmatose 200 M and aqueous HPMC solution | 81.80 | Jethaler and 60 | 34.9 ± 3.7 | [100] |
| SS | Theta-Composer® and 10 | Pharmatose 200 M and MgSt (10%) | 71.8 ± 1.75 | Jethaler and 30 | ~40.00 | [99] |
| SS | Vortex-Mixer and 60 |
Pharmatose 200 M and MgSt (2%) | 87.50 | Jethaler and 60 | 26.0 ± 3.9 | [101] |
| SS | Theta-Composer and 10 |
Pharmatose 200 M and sucrose tristearate (10%) |
71.9 ± 17.5 | Jethaler and 60 | 46.86 ± 1.5 | [102] |
| TNRA | Rotor-type powder mixer (Mechanofusion) and 15 | Pharmatose 325 M and sucrose stearate (1%) | 90 | Jethaler and 30 | 20.90 | [103] |
| TNRA | Rotor-type powder mixer (Mechanofusion) and 15 | Pharmatose 325 M and MgSt (2%) | 85.0 ± 2.0 | Jethaler and 30 | 34.60 | [103] |
| SS | Rotor-type powder mixer (Mechanofusion) | MgSt (5%) | - | Monodose inhaler and 60 | 69.00 | [104] |
| Salmeterol xinafoate | Rotor-type powder mixer (Mechanofusion) | MgSt (5%) | - | Monodose inhaler and 60 | 73.10 | [104] |
SS: salbutamol sulphate; MgSt: magnesium stearate; TNRA: triple neurokinin receptor antagonist; and FPF: fine particle fraction.